Matthew Osborne

Matt is currently a Senior Research Advisor, for manufacturing Sciences, Biotech, Eli Lilly. In this role Matt has responsibilities for biotech manufacturing technical strategy for Lilly’s cell culture platform and will also be involved in developing Lilly’s strategy for manufacturing of ATMP/CGT therapeutics. Prior to this global technical role, Matt held a leadership role for the Biotechnology Manufacturing Sciences department and sat on the site leadership team at the Lilly Kinsale, Ireland site. Over the last 2 years, Matt has also been the manufacturing technical lead for Lilly’s Covid 19 neutralising mAbs programme and has contributed to rapid control strategy development and tech. transfer to multiple manufacturing sites.

Matt has over 20 years experience in process development, technology transfer, process validation, registration and manufacturing support for mammalian and microbial expression systems. Prior to Lilly, Matt has held roles at Cambridge Antibody Technology (Medimmune), Pfizer and UCB Celltech. He joined Lilly in 2008 as Lilly began to establish the biotech product portfolio and commercial manufacturing footprint. He has been heavily involved in manufacturing facility start up and the commercialisation of many of Lilly’s cell culture-based products.

Matt received his BSc in Biotechnology from De Montfort University, Leicester, UK and a Ph.D. in Biochemical Engineering from University College London, London, UK.